Last reviewed · How we verify
Vascular headache — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Norgesic | caffeine | Hikma | Central Nervous System Stimulant [EPC] | Adenosine receptor A2a | 1948-01-01 | |
| Migranal | DIHYDROERGOTAMINE | Bausch Health | Ergotamine Derivative | D(3) dopamine receptor | 1946-01-01 | |
| Ergot | Ergot | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 | |||
| phenobarbitone | phenobarbitone | Institute of Child Health | Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Vascular headache
- Bausch Health · 1 drug in Vascular headache
- Hikma · 1 drug in Vascular headache
- Institute of Child Health · 1 drug in Vascular headache
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital · 1 drug in Vascular headache
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Vascular headache:
- Vascular headache treatment updates — RSS
- Vascular headache treatment updates — Atom
- Vascular headache treatment updates — JSON
Cite this brief
Drug Landscape (2026). Vascular headache — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/vascular-headache. Accessed 2026-06-11.
Related
- Vascular headache full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing